BCA
GILD icon

Bay Capital Advisors’s Gilead Sciences GILD Stock Holding History

Bay Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Sell
1,718
-1
-0.1% -$132 0.12% 101
2026
Q1 		$240K Hold
1,719
– – 0.15% 99
2025
Q4 		$211K Buy
+1,719
New +$209K 0.13% 105

Other funds holding GILD

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Bay Capital Advisors's GILD Position: Q2 2026 in Review

Bay Capital Advisors reduced its Gilead Sciences (GILD) stake by 0.06% in Q2 2026, selling an estimated $132 and leaving 1,718 shares worth $217K. The position accounts for 0.12% of the portfolio, ranked #101.

Bay Capital Advisors first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $240K in Q1 2026. 690 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Bay Capital Advisors held 1,718 shares of Gilead Sciences worth $217K as of Q2 2026.
  • Bay Capital Advisors sold 1 Gilead Sciences share in Q2 2026, an estimated $132.
  • Gilead Sciences made up 0.12% of Bay Capital Advisors's portfolio in Q2 2026, its #101 holding.
  • Bay Capital Advisors first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • Bay Capital Advisors's Gilead Sciences position peaked at $240K in Q1 2026.
  • 690 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Bay Capital Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.